AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31017079 — intervention group
Group type: EXPERIMENTAL
Intervention: CTX‐M‐3 gene
Number of subjects: 314
Study 28276901 — intervention group
Group type: EXPERIMENTAL
Intervention: HolisFiit®, a polyphenol-rich food supplement, daily supplementation for 16 weeks
Number of subjects: 0
Study 25976046 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose levels of 4.4 to 6.1 mmol/L (Group A)
Number of subjects: 90
Study 25976046 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose levels of 6.1 to 8.3 mmol/L (Group B)
Number of subjects: 90
Study 25976046 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose levels of 8.3 to 10.0 mmol/L (Group C)
Number of subjects: 90
Study 25976046 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-septic subjects)
Number of subjects: 90
Study 24079465 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of vertebral fractures in women
Number of subjects: 2887
Study 24079465 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing numbers and severity of fractures in women
Number of subjects: 2887
Study 21892418 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving treatment (PST)
Number of subjects: 202
Study 21892418 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 202
Study 18836440 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin or norepinephrine re‐uptake inhibitors after training
Number of subjects: 0
Study 18836440 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17413648 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 102
Study 17413648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 14687148 — intervention group
Group type: EXPERIMENTAL
Intervention: CDAI remission (CDAI < 150) at week 54
Number of subjects: 573
Study 14687148 — intervention group
Group type: COMPARATOR
Intervention: Percentage of time in CDAI remission
Number of subjects: 573
Study 11246736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based combination chemotherapy
Number of subjects: 0
Study 11246736 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 9015065 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mmol Gd/kg gadoxetic acid disodium
Number of subjects: 15
Study 9015065 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.35 mmol Gd/kg gadoxetic acid disodium
Number of subjects: 15
Study 9015065 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mmol Gd/kg gadoxetic acid disodium
Number of subjects: 15
Study 7957836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized frusemide (40 mg)
Number of subjects: 11
Study 7957836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3602414 — intervention group
Group type: EXPERIMENTAL
Intervention: Amineptine treatment
Number of subjects: 12
Study 3602414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31230500 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Atrial Appendage Closure (LAAC) with the Watchman device
Number of subjects: 10000
Study 31230500 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 10000
Study 31230500 — intervention group
Group type: COMPARATOR
Intervention: Nonwarfarin oral anticoagulants (NOACs)
Number of subjects: 10000
Study 28623954 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg SC Q4W
Number of subjects: 163
Study 28623954 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg SC Q2W
Number of subjects: 163
Study 28623954 — intervention group
Group type: COMPARATOR
Intervention: Placebo Q4W
Number of subjects: 163
Study 28623954 — intervention group
Group type: COMPARATOR
Intervention: Placebo Q2W
Number of subjects: 163
Study 25543310 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid very low calorie diet (VLCD)
Number of subjects: 104
Study 25543310 — intervention group
Group type: COMPARATOR
Intervention: Normal consistency diet
Number of subjects: 104
Study 23391342 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 140
Study 23391342 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine150 (Bupivacaine 0.5% + 150 μg of clonidine)
Number of subjects: 140
Study 23391342 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine250 (Bupivacaine 0.5% + 250 μg of clonidine)
Number of subjects: 140
Study 23391342 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (Control group)
Number of subjects: 140
Study 23391342 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%, Clonidine150, Clonidine250
Number of subjects: 140
Study 21185229 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-week exercise training program (two 1-hour supervised sessions and one 30-minute unsupervised home session per week)
Number of subjects: 34
Study 21185229 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-week exercise training program
Number of subjects: 34
Study 19695029 — intervention group
Group type: EXPERIMENTAL
Intervention: Graph-equipped home blood pressure monitor (n=33)
Number of subjects: 65
Study 19695029 — intervention group
Group type: COMPARATOR
Intervention: Conventional home blood pressure monitor (n=32)
Number of subjects: 65
Study 17404138 — intervention group
Group type: COMPARATOR
Intervention: Children with autism
Number of subjects: 11414
Study 17404138 — intervention group
Group type: COMPARATOR
Intervention: Children with asthma
Number of subjects: 11414
Study 17404138 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with other special health care needs
Number of subjects: 11414
Study 15840108 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser
Number of subjects: 31
Study 15840108 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer lamp
Number of subjects: 31
Study 15840108 — intervention group
Group type: COMPARATOR
Intervention: 311-nm narrowband UVB
Number of subjects: 31
Study 15840108 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser (accelerated scheme)
Number of subjects: 31
Study 15840108 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer lamp (accelerated scheme)
Number of subjects: 31
Study 15840108 — intervention group
Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser and lamp
Number of subjects: 31
Study 11986408 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg, twice-weekly subcutaneous injections)
Number of subjects: 40
Study 11986408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11986408 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 40
Study 11986408 — intervention group
Group type: COMPARATOR
Intervention: Etanercept and Placebo
Number of subjects: 40
Study 9698964 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified double burst stimulation at 50 mA
Number of subjects: 121
Study 9698964 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified double burst stimulation at 30 mA
Number of subjects: 121
Study 9698964 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified double burst stimulation at 20 mA
Number of subjects: 121
Study 7619892 — intervention group
Group type: EXPERIMENTAL
Intervention: CGS 13429A (0.1 to 10 mg)
Number of subjects: 0
Study 2196520 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg twice a day
Number of subjects: 83
Study 2196520 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg twice a day
Number of subjects: 83
Study 2196520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 346161 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 57
Study 346161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 31710012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant + Air Abrasion (AB)
Number of subjects: 30
Study 31710012 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable Composite + Air Abrasion (AB)
Number of subjects: 30
Study 31710012 — intervention group
Group type: COMPARATOR
Intervention: Sealant
Number of subjects: 30
Study 31710012 — intervention group
Group type: COMPARATOR
Intervention: Flowable Composite
Number of subjects: 30
Study 28550459 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric care (CGC)
Number of subjects: 397
Study 28550459 — intervention group
Group type: COMPARATOR
Intervention: Traditional orthopaedic care (OC)
Number of subjects: 397
Study 28550459 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 397
Study 25013088 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine
Number of subjects: 0
Study 25013088 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine and GPC
Number of subjects: 0
Study 25013088 — intervention group
Group type: EXPERIMENTAL
Intervention: DMG and choline
Number of subjects: 0
Study 25013088 — intervention group
Group type: EXPERIMENTAL
Intervention: TMAO
Number of subjects: 0
Study 25013088 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine, DMG, and choline
Number of subjects: 0
Study 24640648 — intervention group
Group type: EXPERIMENTAL
Intervention: Statokinesitherapy with biological feedback
Number of subjects: 0
Study 21228334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg orally on days 1-21 every 28 days until progression or as tolerated
Number of subjects: 217
Study 21228334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide for DLBCL
Number of subjects: 217
Study 21228334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide for MCL
Number of subjects: 217
Study 21228334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide for FL-III
Number of subjects: 217
Study 21228334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide for TL
Number of subjects: 217
Study 21228334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide for all patients
Number of subjects: 217
Study 21228334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide for responders
Number of subjects: 217
Study 21228334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide for patients achieving CR
Number of subjects: 217
Study 21228334 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide for responding patients with FL-III or MCL
Number of subjects: 217
Study 21228334 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to Lenalidomide
Number of subjects: 217
Study 20098825 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 52
Study 20098825 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 52
Study 20098825 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 52
Study 17030175 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral norfloxacin (400 mg twice daily)
Number of subjects: 111
Study 17030175 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ceftriaxone (1 g/day)
Number of subjects: 111
Study 15358018 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty + abciximab
Number of subjects: 2082
Study 15358018 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting + abciximab
Number of subjects: 2082
Study 12575375 — intervention group
Group type: EXPERIMENTAL
Intervention: Qidan Tongmai tablet (QDTMT) in Group A (33 cases without HLC)
Number of subjects: 128
Study 12575375 — intervention group
Group type: EXPERIMENTAL
Intervention: Qidan Tongmai tablet (QDTMT) in Group B (33 cases with HLC)
Number of subjects: 128
Study 12575375 — intervention group
Group type: COMPARATOR
Intervention: Control group C (31 cases without HLC)
Number of subjects: 128
Study 12575375 — intervention group
Group type: COMPARATOR
Intervention: Control group D (31 cases with HLC)
Number of subjects: 128
Study 9032179 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia
Number of subjects: 12
Study 9032179 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 12
Study 9032179 — intervention group
Group type: COMPARATOR
Intervention: Saline VD
Number of subjects: 12
Study 9032179 — intervention group
Group type: COMPARATOR
Intervention: Anesthesia VD
Number of subjects: 12
Study 8436744 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum magnesium (> or = 1.9 mEq/liter)
Number of subjects: 1068
Study 8436744 — intervention group
Group type: EXPERIMENTAL
Intervention: Low serum magnesium (< or = 1.5 mEq/liter)
Number of subjects: 1068
Study 8436744 — intervention group
Group type: COMPARATOR
Intervention: Normal serum magnesium
Number of subjects: 1068
Study 8436744 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomagnesemia
Number of subjects: 1068
Study 8436744 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypermagnesemia
Number of subjects: 1068
Study 3576521 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 10 mg daily for 3 weeks
Number of subjects: 19
Study 3576521 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 30 mg daily for 3 weeks
Number of subjects: 19
Study 3576521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3576521 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 10 mg and 30 mg
Number of subjects: 19
Study 28467150 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (120 mg via nasogastric tube for 15 days)
Number of subjects: 100
Study 28467150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27225859 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005 mg/kg glycopyrrolate
Number of subjects: 84
Study 27225859 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 84
Study 24856612 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily glargine
Number of subjects: 1017
Study 24856612 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily NPH
Number of subjects: 1017
Study 22747603 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gel (CHX-gel) (5.0%)
Number of subjects: 40
Study 22747603 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine/gutta-percha points (CHX-GP)
Number of subjects: 40
Study 22747603 — intervention group
Group type: EXPERIMENTAL
Intervention: Octenidine gel (OCT-gel) (5.0%)
Number of subjects: 40
Study 22747603 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide paste (CH)
Number of subjects: 40
Study 21504570 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed CPG implementation strategy to reduce cardiovascular risk
Number of subjects: 620
Study 21504570 — intervention group
Group type: COMPARATOR
Intervention: Normal dissemination strategy
Number of subjects: 620
Study 18429761 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR/XL
Number of subjects: 0
Study 16927283 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon-alpha plus ribavirin (treatment for persistent HCV infection)
Number of subjects: 33
Study 14499675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillations of Bacillus Calmette-Guerin (BCG) during a 6-week induction course followed by maintenance courses at 3, 6, 12, 18, 24, 30 and 36 months
Number of subjects: 487
Study 14499675 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical instillations of Bacillus Calmette-Guerin (BCG)
Number of subjects: 487
Study 10994660 — intervention group
Group type: EXPERIMENTAL
Intervention: linopirdine (a novel phenylinodolinone)
Number of subjects: 0
Study 10994660 — intervention group
Group type: COMPARATOR
Intervention: global clinical measure
Number of subjects: 0
Study 9114191 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Number of subjects: 100
Study 9114191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 9114191 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine with rash
Number of subjects: 100
Study 9114191 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrimethamine without rash
Number of subjects: 100
Study 8479129 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy with two ampoules of Omnibionta (vitamins C, E, A, and B complex) diluted in 500 ml physiological sodium chloride, infused intravenously prior to reperfusion onset.
Number of subjects: 30
Study 8479129 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antioxidant therapy).
Number of subjects: 30
Study 8479129 — intervention group
Group type: COMPARATOR
Intervention: Comparison between therapy and control groups one hour after reperfusion.
Number of subjects: 30
Study 3310159 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (TH; 234 mg)
Number of subjects: 10
Study 3310159 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-Biphyllin (NB; 600 mg)
Number of subjects: 10
Study 3310159 — intervention group
Group type: COMPARATOR
Intervention: Control (carbachol)
Number of subjects: 10
Study 29569403 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Education System
Number of subjects: 507
Study 29569403 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 507
Study 25995322 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg, three times daily for 12 weeks
Number of subjects: 83
Study 25995322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 24742755 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive and maladaptive emotion regulation strategies during CBT for SAD
Number of subjects: 71
Study 24742755 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual factor: treatment study phase
Number of subjects: 71
Study 23319574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg) on days 1 to 21 (arm 21/28) plus weekly dexamethasone
Number of subjects: 84
Study 23319574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg) continuously (arm 28/28) plus weekly dexamethasone
Number of subjects: 84
Study 19961914 — intervention group
Group type: EXPERIMENTAL
Intervention: Chios mastic gum 350 mg three times daily
Number of subjects: 148
Study 19961914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 17340612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) group
Number of subjects: 96
Study 17340612 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 17153881 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-glucuronidase (BG) treatment
Number of subjects: 125
Study 17153881 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 125
Study 15206735 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (1 g after each meal for 12 days)
Number of subjects: 100
Study 15206735 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 12 days)
Number of subjects: 100
Study 10339997 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural injection of 1 ml (7 mg) bethametason in 10 ml normal saline and 20 ml local anesthetic (Lignocaine 1%)
Number of subjects: 39
Study 10339997 — intervention group
Group type: COMPARATOR
Intervention: Caudal epidural injection of 20 ml local anaesthetic (Lignocaine 1%) and 10 ml normal saline
Number of subjects: 39
Study 10339997 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial injection of 1 ml (7 mg) bethametason around the sacral hiatus
Number of subjects: 39
Study 7676778 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg 0.5% bupivacaine
Number of subjects: 30
Study 7676778 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg 0.5% bupivacaine
Number of subjects: 30
Study 7676778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (25 mg and 30 mg)
Number of subjects: 30
Study 1773154 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav
Number of subjects: 121
Study 1773154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 1773154 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav (children < 2 years)
Number of subjects: 121
Study 1773154 — intervention group
Group type: COMPARATOR
Intervention: Placebo (children < 2 years)
Number of subjects: 121
Study 1773154 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav (children ≥ 2 years)
Number of subjects: 121
Study 1773154 — intervention group
Group type: COMPARATOR
Intervention: Placebo (children ≥ 2 years)
Number of subjects: 121
Study 7353570 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 40
Study 7353570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31027084 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged anticoagulation therapy (median duration: 72.6 hours)
Number of subjects: 114
Study 31027084 — intervention group
Group type: COMPARATOR
Intervention: Brief anticoagulation therapy (median duration: 5 hours)
Number of subjects: 114
Study 31027084 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged anticoagulation therapy
Number of subjects: 114
Study 31027084 — intervention group
Group type: COMPARATOR
Intervention: Brief anticoagulation therapy
Number of subjects: 114
Study 28110155 — intervention group
Group type: EXPERIMENTAL
Intervention: RO5046013 (PEGylated recombinant human insulin-like growth factor-I)
Number of subjects: 62
Study 28110155 — intervention group
Group type: COMPARATOR
Intervention: rhIGF‐I (unmodified recombinant human insulin-like growth factor-I)
Number of subjects: 62
Study 26499007 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride (20 mg syrup for ages 4-6, 40 mg tablet for ages >6)
Number of subjects: 132
Study 26499007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 23987516 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-start controlled ovarian stimulation (COS)
Number of subjects: 128
Study 23987516 — intervention group
Group type: COMPARATOR
Intervention: Conventional-start controlled ovarian stimulation (COS)
Number of subjects: 128
Study 21932560 — intervention group
Group type: EXPERIMENTAL
Intervention: myocardial cytoprotectors (trimetasidin, mexidol, qudesan)
Number of subjects: 1418
Study 19621678 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two mononucleotide markers (BAT26 and BAT25)
Number of subjects: 1531
Study 19621678 — intervention group
Group type: EXPERIMENTAL
Intervention: At least one mononucleotide marker
Number of subjects: 1531